Edition:
United Kingdom

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

3.52USD
19 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.52
Open
$3.50
Day's High
$3.50
Day's Low
$3.50
Volume
37
Avg. Vol
8,298
52-wk High
$5.25
52-wk Low
$2.37

Chart for

About

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.... (more)

Overall

Beta: --
Market Cap(Mil.): $40.32
Shares Outstanding(Mil.): 11.23
Dividend: --
Yield (%): --

Financials

  AZRX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.70 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Azurrx Biopharma Enrolls New Patients For Phase IIA Study Of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY

18 Jan 2018

BRIEF-AzurRx Biopharma receives $2 mln in proceeds from exercise of warrants

* AZURRX BIOPHARMA RECEIVES $2 MILLION IN PROCEEDS FROM EXERCISE OF WARRANTS

17 Jan 2018

BRIEF-AzurRx Biopharma files for mixed shelf offering of up to $10 mln

* AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​ Source text: [http://bit.ly/2z4AEuv] Further company coverage:

01 Nov 2017

Earnings vs. Estimates